Financings in Brief: Norian
This article was originally published in The Gray Sheet
Executive Summary
Norian: Cupertino, California-based developer of the Norian Skeletal Repair System files registration statement with SEC for an initial public offering of 3 mil. shares, expected to be priced between $12 and $14 each. Underwriters Alex. Brown and Robertson, Stephens have an over-allotment option to buy up to 450,000 additional shares. Norian's SRS system incorporates an "injectable, moldable and biocompatible cancellous bone fixation and replacement material" for fracture treatment...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.